COLUMBIA LABORATORIES INC - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 4, 2012

Attached files
FileFilename
EX-31.2 - EXHIBIT 31.2 - COLUMBIA LABORATORIES INCa2012q1ex-312.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR20.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR10.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR5.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR16.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR14.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR13.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR15.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR11.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR12.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR4.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR18.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR1.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR17.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR3.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR7.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR6.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR2.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR8.htm
EXCEL - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR9.htm
EX-32.2 - EXHIBIT 32.2 - COLUMBIA LABORATORIES INCa2012q1ex322.htm
EX-32.1 - EXHIBIT 32.1 - COLUMBIA LABORATORIES INCa2012q1ex321.htm
EX-31.1 - EXHIBIT 31.1 - COLUMBIA LABORATORIES INCa2012q1ex-311.htm
10-Q - CBRX FORM 10-Q - COLUMBIA LABORATORIES INCa2012q110q.htm
v2.4.0.6
Related Party Transactions
 3 Months Ended
Mar. 31, 2012
RELATED PARTY TRANSACTION [Abstract]  
Related Party Transactions Disclosure [Text Block]
RELATED PARTY TRANSACTIONS
The table below presents the transactions between the Company and Watson.
 
Three Months Ended
March 31,
 
 
2012
 
2011
 
REVENUES
 

 
 

 
Net product revenues
$
240,401

 
$
426,780

 
Royalties
600,000

 
540,000

 
Amortization of deferred revenue
—

 
8,393,926

 
Total net revenues
$
840,401

 
$
9,360,706

 
 
 
 
 
 
COST OF PRODUCT REVENUES
 

 
 

 
Cost of product revenues
218,546

 
388,133

 
Gross profit
$
621,855

 
$
8,972,573

 
 
 
 
 
 
 
 
 
 
 
Accounts receivable
$
1,256,203

 
$
555,441

 

The Company has exceeded the cap of $7.0 million by $3.6 million for R&D spending on the PREGNANT study and related Preterm Birth NDA pursuant to the Watson Transactions and has recorded this amount as a reduction of R&D expenses. Watson has paid the Company for $3.2 million of these excess amounts and has been invoiced for the remaining $0.4 million equal to the R&D expense reimbursement recognized in the first quarter of 2012.

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by COLUMBIA LABORATORIES INC and has no official or unofficial affiliation with COLUMBIA LABORATORIES INC


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.